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Introduction: Administration of a placebo associates with symptomatic improvement in many conditions e
the so-called placebo response. In this review we explain the concept of placebo response, examine
the data that supports existence in osteoarthritis (OA), and discuss its possible mechanisms and
determinants.
Methods: A Pubmed literature search was carried out. Key articles were identiﬁed, and their ﬁndings
discussed in a narrative review.
Results: Pain, stiffness, self-reported function and physician-global assessment in OA clearly improve in
response to placebo. However, more objective measures such as quadriceps strength and radiographic
progression appear less responsive. Although not directly studied in OA, contextual effects, patient
expectation and conditioning are believed to be the main mechanisms. Neurotransmitter changes that
mediate placebo-induced analgesia include increased endogenous opioid levels, increased dopamine
levels, and reduced levels of cholecystokinin. Almost all parts of the brain involved in pain processing are
inﬂuenced during placebo-induced analgesia. Determinants of the magnitude of placebo response
include the patientepractitioner interaction, treatment response expectancy, knowledge of being
treated, patient personality traits and placebo speciﬁc factors such as the route and frequency of
administration, branding, and treatment costs.
Conclusion: Clearer understanding of the neurobiology of placebo response validates its existence as a
real phenomenon. Although routine administration of placebo for symptomatic improvement is difﬁcult
to justify, contextual factors that enhance treatment response should be employed in the management of
chronic painful conditions such as OA where available treatments have only modest efﬁcacy.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The word ‘placebo’ (Latin: I shall please) came into common use
with St. Jerome’s incorrect translation of the ﬁrst word of the ninth
line of the 116th psalmwhere he translated the Hebrew ‘I will walk
before the Lord’, to ‘I will please the Lord’1. The hired funeral
mourners in fourteenth century Europe who frequently chanted
this incorrect translation repetitively were called the ‘placebos’1.
Therefore, it is not surprising that ‘placebo’ which implied decep-
tion and substitution in the middle ages was the name chosen by
Chaucer for a ﬂattering courtier in his book the Canterbury Tales2.
The ﬁrst published medical use of the word placebo was in the
New Medical Dictionary (c 1785), in which it was described as ato: A. Abhishek, Academic
NG5 1PB, United Kingdom.
bhishek), michael.doherty@
s Research Society International. Pcommonplace method or medicine2. Similarly, in the biomedical
context placebo is any inert substance, such as a lactose pill or a
fake procedure (e.g., sham acupuncture), which is not expected to
improve either the symptom or the disease process. Paradoxically,
the administration of a placebo associates with symptomatic
improvement in a number of conditions, the so called placebo
response (Syn.: placebo effect)3. The placebo response does not
result from the inert substance itself but is due to the therapeutic
ritual, context effects, and expectation of improvement that
accompany its administration. Placebo response was recognized as
far back as the eighteenth century. For example, in 1811, the revised
Quincy’s Lexicon-Medicum deﬁned placebo as ‘an epithet given to
any medicine adapted more to please than to beneﬁt the patient’2.
However, it is important to dissociate placebo and contextual re-
sponses, which can be optimized to advantage in the management
of chronic diseases, from the deceitful and currently unethical
administration of placebo to achieve improvement in symptoms. In
this review, we will explain the concept of placebo response,
examine the data that supports its existence in osteoarthritis (OA),ublished by Elsevier Ltd. All rights reserved.
Box 2
Predictors of magnitude of placebo response in OA pain
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summary of the deﬁnition, mechanisms, determinants, neuro-
pharmacology, and neuro-anatomy of placebo response based on
supporting evidence. This is not a systematic or exhaustive review
of the literature on placebo responsiveness.
What is placebo response?
Placebo response is the symptomatic improvement experienced
by a patient on receiving an intervention, or a set of interventions
that are regarded as inert and non-therapeutic for the condition
(‘placebo’) compared to those who receive no such intervention(s).
Placebo response is believed to be predominantly due to the
context in which it is administered i.e., the special interaction be-
tween the patient and the healthcare practitioner which is inti-
mately associated with the delivery of treatment4. This was
highlighted by Shapiro, Gotzsche, and Brody in their deﬁnitions of
placebo effect (Box 1)5e7.
Placebo response is not necessarily equivalent to the improve-
ment in symptoms observed in the control (or ‘placebo’) arm of
randomized control trials (RCTs). The symptomatic improvement
observed in the control arm of RCTs can be inﬂuenced by many
factors other than the placebo response including regression
to the mean, natural variation in disease severity, spontaneous
improvement, additional undeclared treatments, Hawthorne effect
(behaviour change through being observed) and response bias8.
Therefore, placebo response can only be reliably measured in RCTs
when there is both a placebo and a ‘no-treatment’ (simple obser-
vation) comparator group, the difference between these indicating
the improvement that results from the placebo response alone.
However, since most RCTs do not have a ‘no-treatment arm’ this
distinction is often obfuscated by many researchers.
What is the evidence for existence of a placebo response?
In a landmark paper reviewing 15 RCTs in 1955, Henry Beecher
reported that 35% patients improved in the placebo arm of these
studies3. This paper which kindled much interest in placebo
response was criticized since only two trials included a no-
treatment arm, and none of these demonstrated a placebo
response2,9.
However, since then studies have found evidence for a placebo
response in several conditions4,10,11. In a systematic review and
meta-analysis comparing placebo and no-treatment, placebo
response was most evident in the treatment of pain (pooled stan-
dardized mean difference (SMD) (95% conﬁdence interval
(CI)) 0.27 (0.40 to 0.15))10. A subsequent systematic review11,
and a recent Cochrane review4 carried out by the same groupBox 1
Definitions of placebo response (syn. placebo effect)
Brody A change in a patient’s illness attributable to the symbolic
import of a treatment rather than a speciﬁc pharmacologic or
physiologic property5.
Gotzsche The difference in outcome between a placebo treated group and
an untreated control group in an unbiased experiment6.
Shapiro The psychological or psycho-physiological effect produced by
placebos7.
Doherty Symptomatic improvement on receiving any inert/non-
therapeutic (‘placebo’) intervention(s) compared to those who
do not receive it.conﬁrmed that placebo response in RCTs occurs in the treatment of
pain (pooled SMD (95% CI) 0.28 (0.36 to 0.19)), nausea (pooled
SMDwas0.25 (0.46 to0.04)), and possibly phobia and asthma.
However, the authors suggest that the latter two associations may
be biased4. The existence of a placebo response in pain is also
supported by systematic reviews of neuropathic pain and OA
RCTs8,12. Placebo response is independent of age and social and
physical demographics, but may be inﬂuenced by gender (men
showing greater placebo-induced reduction in heat-induced pain
and anticipatory stress than women)13.
Although some placebo responses mediated by conditioning
(see later) may mimic biological functions such as drug induced
immunosuppression14,15, recent systematic reviews suggest that
placebo response is mainly observed when continuous subjective
measures of disease activity are used, and not when binary sub-
jective or objective (physical or laboratory) measures of disease
activity are used4,10,11. This suggests that placebo does not affect
disease pathophysiology per se but does have a mild-moderate ef-
fect on symptoms sufﬁcient to inﬂuence the continuous subjective
measures of disease activity. However, such signiﬁcant improve-
ment in symptomsmay be beneﬁcial in the management of chronic
conditions like OA where most physical and pharmacological
treatments have only a mild or modest effect size (ES)16.What is the evidence for the existence of a placebo response
in OA?
A systematic review and meta-analysis involving 193 placebo
(16,364 patients) and 14 untreated control groups (1,167 patients)
from OA RCTs conﬁrmed that placebo response occurs in OA8. In
this review, the presence of placebo responsewas examined in RCTs
that investigated a wide range of non-pharmacological, pharma-
cological, and invasive treatments. The key results are:
 Pain in OA is responsive to placebo (Box 2).
B Overall ES (95% CI) for pain relief is 0.51 (0.46e0.55) for
placebo, and 0.03 (0.13 to 0.18) for untreated controls.
B In three head to head trials where placebo and no-treatment
arms were present the ES of placebo was greater, with
overall ES (95% CI) of 0.77 (0.65e0.89) for placebo,
and 0.08 (0.65e0.48) for untreated controls.
B Greater pain relief from placebo was observed in trials that
did not allow rescue medications, perhaps due to a greater
expectancy of pain relief in these trials.Treatment effect
size (ES)*
The higher the ES the greater the placebo response,
possibly due to high expectation of beneﬁt.
Baseline pain* Higher baseline pain results in greater placebo
response.
Invasive route of
delivery*
Repeated needling e.g., acupuncture, intra-articular
hyaluronan, and repeated intra-articular
corticosteroid injections have very high placebo
effects.
Joint with OAy Placebo response magnitude reduces from hands, to
knee to hip.
Topical
applicationz
Topical NSAID application has a high placebo effect.
* Statistically signiﬁcant.
y Not statistically signiﬁcant.
z Not examined in multivariate model.
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strate a larger placebo response, most likely due to the need
for a greater power to separate a clinically meaningful effect
of the intervention above that of placebo.
 Placebo response was also present in other subjective out-
comes such as stiffness (ES (95% CI) 0.43 (0.38e0.49)), self-
reported function (ES (95% CI) 0.49 (0.44e0.54)), and physi-
cian’s global assessment (ES (95% CI) 0.66 (0.53e0.78)).
 Placebo response was not present for most objective outcomes
such as quadriceps strength, knee swelling circumference,
range of movement, and radiographic joint space narrowing.
 For objective measures which require patient co-operation and
effective analgesia e.g., timed speciﬁed walking distance, pla-
cebo had an intermediate ES (95% CI) (0.22 (0.08e0.35))
compared to the ES for placebo analgesia in the same studies.
What is the mechanism of placebo response?
Although not studied speciﬁcally in OA, there is a signiﬁcant
literature on the mechanism of placebo response in pain, behav-
ioural sciences, and Parkinson’s disease. Expectation and condi-
tioning are believed to be the principal mechanisms of placebo
response17. Verbal, conditioned, and observational clues can
create strong expectations which mediate the placebo response17.
Other mediators of placebo response include verbal suggestion
mediated relief in anxiety, previous experience of effectiveness,
and observing drug effectiveness in others in a social context
without any deliberate reinforcement18e20. Reward mechanisms
have also been implicated to be activated during placebo
response21. It is likely that all mechanisms interact to drive the
placebo response. Studies over the last 30 years have deﬁned
the neuro-pharmacology, and the neuro-anatomy of placebo
response. In this review we focus on the neurobiology of placebo
analgesia.
Neuro-pharmacology of placebo response
Placebo analgesia appears to be mediated predominantly by
enhancement of descending inhibitory systems. High levels of
endogenous opioids, dopamine release, and low levels of chole-
cystokinin (CCK) are implicated as the principal pharmacologic
mediators of placebo analgesia. Of these, the strongest evidence
exists for the role of endogenous opioids acting predominantly via
their m-receptors22e25. For example, in a PET study measuring in-
vivo receptor binding in which a m-opioid receptor selective
radiotracer [11C] carfentanil bound to the available m-opioid re-
ceptors, the administration of a placebo reduced the uptake of this
radiotracer by the m-opioid receptors and the reduction in binding
correlated with analgesia22. In previous classic studies involving
tooth extraction26 and ischaemic arm27 models of pain, naloxone
(an opiate antagonist) blocked the placebo response induced by
verbal suggestion, and by verbal suggestion with a preconditioning
procedure designed to further induce the expectation of analgesia.
Similarly, the CSF concentration of endogenous opioids is higher in
chronic pain patients who are placebo responders than in those
who are placebo non-responders28. Placebo-activated endogenous
opioid systems also act on the respiratory centre to induce respi-
ratory depression29, reduce the b-adrenergic activity of the heart30,
and these effects are blocked by naloxone. The key role of opioids in
mediating placebo analgesia is further supported by the fact that
the coupling between the cerebral cortex and the subcortical anti-
nociceptive networks such as the peri-aqueductal grey (PG) and the
amygdala nuclei is mediated by opioids24,25,31. Similarly, the
increased activity within the descending pain modulatory pathway
that accompanies placebo analgesia is principally mediated byopioids22,25. However, not all placebo-induced analgesia is medi-
ated by endogenous opioid. A tooth extraction study showed that
placebo analgesia could still occur despite the presence of an opioid
antagonist (naloxone) suggesting that placebo effects can occur
independent of opioid mechanisms32. Similarly, while placebo
analgesia produced by expectation and prior conditioning with
opiate analgesics is mediated by the release of endogenous opioids,
placebo analgesia produced by prior conditioning with ketorolac, a
non-steroidal anti-inﬂammatory drug (NSAID), is not mediated by
the release of endogenous opioids as it is naloxone insensitive27.
These studies conﬁrm that there are neurochemical mechanisms of
placebo analgesia other than opioids and that conditioning with
different classes of analgesic drugs may result in different stimulus-
speciﬁc mechanisms of analgesia.
Dopamine release which mediates the motor placebo response
in Parkinson’s disease also mediates placebo analgesia21. In an
experimental pain model activation of dopamine in the nucleus
accumbens (NA) was related to both placebo responsiveness and to
monetary reward21. There was a strong correlation between NA
activation in placebo analgesia and response to monetary reward,
suggesting that reward mechanisms mediated by dopaminergic
transmission may in part mediate placebo responsiveness21. In a
study of 20 healthy volunteers aged 20e30 years, dopamine and
opioid neurotransmission was shown to be increased in states of
placebo analgesia and conversely reduced during nocebo states
(nocebo is when symptoms are worsened or induced by an inert
treatment)33. Interestingly NA activation explained 28% of the
variance in placebo analgesia, suggesting that dopamine may have
a signiﬁcant role in placebo analgesia33. However, this study was
carried out in healthy individuals and the ﬁndings need to be
conﬁrmed in patients with chronic painful conditions like OA.
Further evidence supporting the role of dopamine in placebo
response is provided by a study of sham acupuncture in peoplewith
irritable bowel syndrome (IBS) where the effect of no-treatment
(“waiting-list” observation group), placebo treatment alone
(“limited” sham acupuncture) and placebo treatment “augmented”
with a supportive patient-health care provider interaction were
compared using the IBS symptom severity scale34. These patients
were genotyped for the val158met polymorphism in the catechol-
O-methyltransferase (COMT) gene. Patients with the met/met
polymorphism e which associates with reduced dopamine catab-
olism e had a greater placebo response than those with a val/val
polymorphism, whereas those with val/met polymorphism had an
intermediate placebo response34. Constitutional genetic variation
in pain physiology may therefore inﬂuence placebo analgesia.
CCK, the other neurochemical mediator of placebo response,
inhibits placebo analgesia35. This is supported by the fact that
proglumide, a CCK antagonist, enhances placebo analgesia35 and
blocks the hyperalgesic nocebo response36. Thus CCK and opiates
antagonize each other in the generation of placebo analgesia.
However, the nocebo response is not blocked by naloxone sug-
gesting that it is not mediated by the opioid pathway36. Serotonin
(5-HT) which mediates placebo-induced increase of growth hor-
mone secretion, and decreased cortisol secretion after pharmaco-
logical preconditioning with sumatriptan has not been implicated
in mediation of placebo analgesia37.
Neuro-anatomy of placebo analgesia
Several neuroimaging studies have identiﬁed areas of the brain
that are involved in placebo response (Fig. 1). Almost all parts of the
pain pathway are inﬂuenced during placebo analgesia (Box 3). Parts
of the frontal lobe e.g., the pregenual rostral anterior cingulate
cortex (RACC), dorsolateral prefrontal cortex (PFC), and orbito-
frontal cortex are activated during both the anticipatory and late
Box 4
Determinants of placebo response
NA
VTA
PG
PFC 
H
RVM
DH
Fig. 1. Neuro-anatomical basis of placebo analgesia. Placebo analgesia is mediated by
dopaminergic (yellow in diagram) transmission from the ventral tegmental area (VTA)
to the NA, and by opioidergic (red in diagram) transmission from the cerebral cortex e
predominantly the PFC to the PG in the midbrain, which in turn projects to the rostral
ventral medulla (RVM), and to the dorsal horn ganglia (DH) in the spinal cord. The
opioidergic pain modulating pathway also projects to the hypothalamus (H).
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frontal lobe activation drives changes in other parts of the brain in
response to at least some types of placebos. For example, frontal
lobe disconnection either induced experimentally by trans-cranial
magnetic stimulation, or due to Alzheimer’s disease associates
with a loss of verbally induced placebo responses40,41. Cortical, for
example RACC activation stimulates subcortical anti-nociceptive
networks such as the PG and amygdala nuclei24,25,31. During pla-
cebo analgesia there is increased activity within the descending
pain modulatory pathway22,25, and reduced activity in the noci-
ceptive pain processing pathways in the dorsal horn of the spinal
cord42. Deeper parts of the cortex, such as the NAwhich is involved
in the reward mechanism, and parts of the insula are also activated
during placebo analgesia33. The activity of regions involved in painBox 3
Parts of brain involved in placebo analgesia
Frontal cortex and limbic system
Subcortical reward mechanism
Sub-cortical pain transmission centres
Descending pain modulatory pathway
Nociceptive pain processing pathways in the dorsal horn of the spinal
cordtransmission, such as the thalamus, anterior insula, and caudal
RACC, are decreased by placebo indicating a reduction in nocicep-
tive transmission in the pain pathways39.
What are the determinants of placebo response?
In order to harness the phenomenon of placebo response in
routine clinical practise it is important to understand the predictors
of the magnitude of placebo response. The key physician, patient,
and intervention speciﬁc determinants of placebo response sum-
marized in Box 4 are discussed below.
Context of the consultation
A warm consultation provided by a conﬁdent physician who is
perceived as competent by the patient and who provides a good
outlook results in a larger placebo response43e47. In the study
mentioned above of sham acupuncture in IBS patients randomized
to waiting list (assessment and observation), sham acupuncture
with only limited patientepractitioner interaction (therapeutic
“ritual”), or sham acupuncture with the usual patientepractitioner
interaction augmented by warmth, attention and conﬁdence
(augmented interaction) the augmented treatment associated with
62% of patients reporting pain relief at 3 weeks, while 28% of the
observation only and 44% of the limited “ritual” group reported
pain relief43. Similarly, in a primary care based study of 200 patients
with various symptoms but no abnormal signs, those given a
“positive” consultation comprising of a conﬁdent diagnosis and
reassurance that things would improve soon were approximately
twice as likely to feel better than a “negative” consultation, where
the doctor admitted “I cannot be certain of what is the matter with
you”. The option of being prescribed a placebo (thiamine tablets)
did not affect the feeling of improvement44. The overriding factor
that improved symptoms appeared to be the patient response to
the certainty of diagnosis and reassurance concerning prognosis44.
Other contextual aspects that may promote a positive placebo
response include: the patient’s perception that the practitioner is
experienced and competent45,46; an optimistic clinician who sug-
gests that the treatment will help45,46, and when the practitioner
wishes to see the patient again to monitor progress47.
Clinician’s conﬁdence in treatment
Patients are inﬂuenced by the clinician’s optimism or pessimism
concerning the treatment even if this feeling is subconscious and
not explicitly expressed. For example, in a double blind dental painPhysician factors Warm, attentive, conﬁdent, and optimistic ‘positive
consultation’.
Physician’s optimism about treatment, reassurance
about prognosis, and desire to follow-up.
Patient factors Perception that the physician is competent.
Patient’s expectation of what an intervention will
do to them.
Knowledge of being treated.
Personality factors e.g., optimism, state anxiety.
Placebo
(intervention)
factors
Invasive, frequent interventions.
Reputable brand, higher cost, and greater number
of tablets.
Colour of tablets.
A. Abhishek, M. Doherty / Osteoarthritis and Cartilage 21 (2013) 1229e1235 1233study, patients could either receive fentanyl (to reduce pain),
naloxone (to potentially increase pain), or a placebo48. In this study,
the investigators were told that the ﬁrst group of patients could
only receive naloxone or placebo (i.e., no active analgesic), and that
the second group of patients could receive fentanyl, naloxone, or
placebo. In fact all three drugs were administered to both groups in
a double blind fashion. Interestingly, therewas less improvement in
pain after the administration of placebo in the ﬁrst group of pa-
tients than in the second group of patients48. This suggests that the
clinician’s pessimism or optimism about the proportion of patients
receiving the active drug, was unintentionally transmitted to the
patient and inﬂuenced treatment efﬁcacy48.
Response expectancy, concealment and knowledge of being treated
The patient’s expectation of what an interventionwill achieve is
an important determinant of placebo response. In a study of effects
of aerobic exercise on physical capacity, patients whowere told that
they would also feel better as a result of the intervention reported
an improvement in their wellbeing despite having a similar
improvement in their aerobic capacity when compared to the
group of patients whowere not given this information and who did
not report such improved wellbeing49. Similarly, study participants
given decaffeinated coffee but who were told that they would all
receive regular coffee (i.e., 100% expectancy of caffeine) had a
greater increase in alertness, heart-rate, and blood pressure than a
group of participants who were told that they would receive either
regular or decaffeinated coffee (i.e., only a 50% chance of receiving
caffeine)50.
Knowing that a treatment is being administered is important. In
a post-operative analgesia study covert administration of paren-
teral morphine resulted in slower onset of pain relief than when
patients knewwhen themorphinewas administered, implying that
the initial rapid relief from our strongest analgesic is largely
effected through a placebo response51. Similarly, open discontinu-
ation of morphine led to rapid return of pain whereas covert
discontinuation did not51.
Personality effects
In a recent reviewWatson et al. suggested that personality traits
such as optimism, pessimism, trait anxiety, and neuroticism inﬂu-
ence the placebo response52. Optimismmay inﬂuence the extent to
which a patient given a placebo treatment persists in the treated
state and interprets it positively. In a recent study involving
experimental placebo analgesia (inert cream) tested on two sepa-
rate occasions, optimists experienced greater and more reproduc-
ible placebo analgesia53. On the contrary, pessimists are more likely
to be inﬂuenced by negative expectations. For example, in one
experiment pessimistic healthy volunteers reported feeling worse
after receiving negative expectation about the placebo adminis-
tered54. People with state anxiety (‘situational anxiety’) show pla-
cebo response, but not those with trait anxiety (‘habitually
anxious’)52. This may be because state anxiety reﬂects respon-
siveness to the context whereas trait anxiety, an intrinsic person-
ality trait, is independent of the environment52. In an experimental
study involving IBS patients, reduction in state anxiety after the
ﬁrst placebo session correlated with placebo analgesia after the
second session55.
Method and frequency of administration
In general, the more invasive and the more frequently admin-
istered an intervention the higher the placebo effect8. Sham
arthroscopy in the context of OA, and sham bilateral ligation of theinternal mammary artery (BIMAL) in the context of angina, both
associate with the same high rate of symptom improvement as the
actual treatments, and despite the absence of a no-treatment
control group in these studies, they suggest that surgery associ-
ates with a very large placebo response56e58.
Colour and number
Medical students given either a blue or a pink tablet containing
an inert substance and told that onewas a stimulant and the other a
sedative, reported that pink tablets caused stimulant effects and
blue tablets sedation, and those receiving two tablets reported
greater effects than those receiving one59. These effects are
explained by the meaning associated with the colour (pink for hot,
blue for cool) and the expectancy that a double is more potent than
a single dose. One systematic review concluded that green and blue
may have more sedative, and red and orange more stimulant ef-
fects60. In an Italian study, however, blue tablets had a sedative
effect in women but an opposite effect in men, perhaps because
blue is the national soccer team colour and associates with
excitement in men61. Thus, it is the meaning attributed to a colour
by an individual, not the colour itself that inﬂuences the outcome
(“meaning response”)62.
Branding and cost
Brand, expense, and novelty of treatment clearly inﬂuence the
placebo response62e65. In a placebo-controlled trial of aspirin for
headache, patients were randomized to either: aspirin labelled
with a well-known brand; unbranded aspirin; placebo marked
with the same brand; or plain placebo. Aspirin was more effective
than placebo, and branded tablets (both active and placebo) were
more effective than their unbranded counterparts63. In another
study, patients who were told that their tablets were obtained at
full cost had better pain relief than those who were informed
that their tablets were heavily discounted64. Similarly ‘new’ in-
terventions have a greater placebo response than well-established
older treatments62,65. This has been shown for a number of drugs
that have been examined in similar study designs over many years,
including paracetamol for OA66, in which the ES of both active and
placebo treatments diminishes with time.
Placebo response e not all is in the mind
While the studies presented so far suggest that placebo
response originates in the brain, several other studies have
demonstrated that placebo can inﬂuence physiology in other body
systems including leucocyte count15 and physical function14. For
example, in one study, multiple sclerosis patients were treated at
regular intervals initially with cyclophosphamide paired with anise
ﬂavoured syrup but then with placebo plus the same syrup. After
the switch, eight out of 10 patients showed a similar decrease in
leucocyte count on placebo plus syrup as was achieved with
cyclophosphamide plus syrup15. In a similar classic conditioning
study involving healthy individuals treated initially with cyclo-
sporine paired with a ﬂavoured drink but subsequently placebo
with the same drink, measurable reductions in leucocyte
interleukin 2 (IL-2) and interferon (IFN)-ɣ mRNA expression,
intracellular production and release of IL-2 and IFN-ɣ, and
lymphocyte proliferation in vitro were obtained by administration
of the placebo capsules and ﬂavoured drink alone14. These studies
suggest that behavioural conditioned immunosuppression is
possible in humans. However, although these studies provide an
insight into the extent of placebo responsiveness, this approach is
not applicable to clinical practice.
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Placebo and contextual effects should be recognized and opti-
mized in routine clinical care, especially in the management of
chronic distressing conditions for which there are no deﬁnitive
treatments. While it is unreasonable to consider changing a treat-
ment to make it more invasive, frequent, or expensive to elicit a
placebo response; it is important to have a positive consultation, to
assess the patient thoroughly, to fully inform the patient and show
conﬁdence in treatment offered, and to follow-up the patient to see
how they are doing. This is especially true in conditions like OA
where the ES of placebo (0.5e0.7) is larger than that achieved with
most conventional pharmacological therapies such as oral analge-
sics and NSAIDs (0.2e0.3)16. However, it is debatable when it be-
comes unethical to increase expectations in this manner67. Is it
correct for the healthcare professional to induce more expectation
for effective interventions, and less expectation for the less-
effective interventions per-se? While it may seem reasonable to
optimize placebo response in the context of medically proven in-
terventions, the use of ineffective interventions to elicit placebo
response alone is controversial, and may be difﬁcult to justify, both
ethically and ﬁnancially. However, the fact that active treatment
associates with concomitant contextual effects should be recog-
nized and utilized in routine clinical practise48.
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